HC Wainwright Increases ProQR Therapeutics (NASDAQ:PRQR) Price Target to $12.00

ProQR Therapeutics (NASDAQ:PRQR) had its price objective hoisted by equities researchers at HC Wainwright from $10.00 to $12.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock.

Other analysts also recently issued reports about the stock. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. Oppenheimer started coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 price objective for the company. Chardan Capital restated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Monday, March 10th. Finally, JMP Securities restated a “market outperform” rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.50.

ProQR Therapeutics Stock Down 2.9 %

PRQR stock opened at $1.69 on Friday. The company has a market capitalization of $138.04 million, a price-to-earnings ratio of -5.28 and a beta of 0.24. ProQR Therapeutics has a 12 month low of $1.61 and a 12 month high of $4.62. The firm has a 50 day moving average of $2.25 and a two-hundred day moving average of $2.62.

Hedge Funds Weigh In On ProQR Therapeutics

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in ProQR Therapeutics during the 4th quarter valued at $30,000. Invesco Ltd. acquired a new position in ProQR Therapeutics during the 4th quarter valued at $32,000. Alpine Global Management LLC acquired a new position in ProQR Therapeutics during the 4th quarter valued at $39,000. Two Sigma Securities LLC acquired a new position in ProQR Therapeutics during the 4th quarter valued at $40,000. Finally, ADAR1 Capital Management LLC acquired a new position in ProQR Therapeutics during the 4th quarter valued at $54,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).